Former Aimmune Exec Stephen Dilly Named Sierra Oncology’s New CEO

Sierra Oncology (NASDAQ: [[ticker:SRRA]]) has appointed Stephen Dilly to serve as its president and CEO starting June 1. He is also joining the Vancouver, BC-based company’s board of directors. Dilly retired as CEO of Aimmune Therapeutics (NASDAQ: [[ticker:AIMT]]) in 2018. His experience also includes positions at Genentech, Chiron BioPharma, and SmithKline Beecham. Sierra acquired its lead drug candidate, momelotinib, from Gilead Sciences (NASDAQ: [[ticker:GILD]]) in 2018. The small molecule is currently in Phase 3 testing as a potential treatment for myelofibrosis, a bone marrow cancer.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan